7/102 sources · 2 publishersUpdated Nov 8, 20:51 UTC
TransMedics shares jump 25% after Q3 earnings beat and raised 2026 revenue outlook
TransMedics reported third‑quarter results that topped analysts' expectations, prompting the stock to climb more than 25% on November 6. The company also lifted its 2026 revenue guidance to a range of $764 million‑$774 million, up from the prior $737 million‑$757 million. The new outlook adds $14 million of revenue from the PAD Aviation partnership.
Why it matters
The higher revenue forecast suggests stronger future cash flow, which could support a higher valuation for the company. Investors may price in the added $14 million from PAD Aviation when assessing the stock.
Key facts
- 1Shares rose over 25% on November 6 after the Q3 earnings release. seekingalpha.com
- 2Q3 results exceeded expectations. seekingalpha.com
- 32026 revenue outlook was raised to $764 million‑$774 million. tokenpost.com
- 4Previous 2026 revenue outlook had been $737 million‑$757 million. tokenpost.com
- 5The new forecast includes $14 million from PAD Aviation. tokenpost.com
Summary written by AlphAI AI Desk from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.